Given their crucial role in gene regulation, HATs are considered potential therapeutic targets. HAT inhibitors are being developed to modulate their activity in diseases characterized by abnormal acetylation patterns. For example, specific inhibitors targeting p300/CBP have shown promise in preclinical cancer models, indicating the potential for HAT-focused therapies in clinical settings.
